Literature DB >> 1907351

Enhancer mediated suppression of epsilon heavy-chain gene expression in a murine IgE-producing hybridoma.

K Nelms1, B G Van Ness, R G Lynch, A Mathur.   

Abstract

In vitro co-culture of IgE-secreting hybridoma cells (B53) with spleen cells harvested from mice with established B53 tumours results in a specific, T cell-dependent suppression of epsilon-chain expression in the B53 cells. The role of immunoglobulin enhancers in the suppression of IgE synthesis in B53 cells was examined by transfecting B53 cells with CAT expression vectors containing the immunoglobulin heavy- or kappa light-chain intron enhancers or a Rous sarcoma virus (RSV) LTR. When epsilon-chain expression of transfected cells was suppressed in vitro. CAT expression was also suppressed in cells transfected with vectors containing the immunoglobulin heavy-chain gene enhancer, but not in cells transfected with vectors containing the kappa enhancer or RSV LTR. Thus, the T cell-dependent suppression of IgE synthesis in B53 cells correlates with a specific inactivation of the immunoglobulin heavy chain enhancer, strongly suggesting that T cell-mediated suppression of Ig synthesis can normally occur through specific repression of Ig enhancer function. This represents a new regulatory pathway involved in the control of IgE synthesis and is the first indication that the enhancer mediated expression of Ig genes in B cells can be modulated through T cell-dependent processes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1907351     DOI: 10.1016/0161-5890(91)90128-7

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  2 in total

Review 1.  Rous-Whipple Award lecture. The biology and pathology of lymphocyte Fc receptors.

Authors:  R G Lynch
Journal:  Am J Pathol       Date:  1998-03       Impact factor: 4.307

Review 2.  The biology and pathology of Fc receptors.

Authors:  M Sandor; R G Lynch
Journal:  J Clin Immunol       Date:  1993-07       Impact factor: 8.317

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.